Z Squared Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 68/100
What the filing says
Effective April 15, 2026, Coeptis Therapeutics Holdings Inc. (the filer, per filing header) transferred equity securities—including 100% of Coeptis Therapeutics Inc., 100% of Coeptis Pharmaceuticals Inc., and 7,300,000 shares (73%) of SNAP Biosciences—to newly formed subsidiary Coeptis Holdings Inc. via contribution agreement. Simultaneously, operating assets including contracts, 2,696,203 Jabez Biosciences shares, 2,994,880 NOK Therapeutics shares, and three promissory notes were assigned to Coeptis Therapeutics Inc. On April 24, 2026, a separate option agreement granted Coeptis Holdings Inc. (Option Holder) a 24-month option to purchase 8,300,000 Class A shares (100% of Class A, 83% total ownership) of GEAR Therapeutics Inc. from the parent for fair market value, exercisable starting October 24, 2026. All three agreements were signed by CEO David Mehalick on behalf of both parties.
Why this rating
Complex internal restructuring involving material asset transfer and contingent option (~possibly significant value) relative to $28.2M market cap; lack of pricing clarity and operational rationale limits assessment, but restructuring scope is substantial and structure suggests strategic repositioning or preparation for future transaction.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.